Filing Flows › Karyopharm Therapeutics (KPTI) › Q2 2026 › vs Q1 2026
Karyopharm Therapeutics (KPTI) Q2 2026 vs Q1 2026 (quarter over quarter)
Karyopharm Therapeutics's revenue fell $1.6M (-5%) from $35.1M in Q1 2026 to $33.4M in Q2 2026. The biggest changes: License and Other −$3.2M (-55%); Product +$1.6M (+6%).
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $30.8M | $29.2M | $1.6M | +6% |
| License and Other | $2.7M | $5.9M | −$3.2M | -55% |
| Revenue | $33.4M | $35.1M | −$1.6M | -5% |
| Net loss | $67.0M | $22.4M | $44.6M | +199% |
| Costs & expenses | $100M | $61.8M | $38.6M | +62% |
| Operating costs | $56.0M | $61.8M | −$5.9M | -9% |
| Interest & other, net | $44.5M | −$4.4M | $48.9M | — |
| Research & development | $29.0M | $33.8M | −$4.8M | -14% |
| SG&A | $25.9M | $26.7M | −$768K | -3% |
| Other operating costs | $1.1M | $1.3M | −$260K | -19% |
| Operating cash sources | $67.0M | $22.4M | $44.6M | +199% |
| Share-based compensation | $1.9M | $3.0M | −$1.1M | -36% |
| Working capital & other | $40.2M | −$3.4M | $43.5M | — |
| Cash used in operations | $24.9M | $22.7M | $2.2M | +10% |
| Net loss absorbed | $67.0M | $22.4M | $44.6M | +199% |
Questions
How much did Karyopharm Therapeutics's revenue grow quarter over quarter in Q2 2026?
Karyopharm Therapeutics's revenue fell $1.6M (-5%) from $35.1M in Q1 2026 to $33.4M in Q2 2026.
What drove Karyopharm Therapeutics's revenue change in Q2 2026?
License and Other −$3.2M (-55%); Product +$1.6M (+6%).